C2-Social prescribing: the need for an ongoing policy dialogue to inform decision making and improve the health of the population
Podium 3
2:00 PM - 2:30 PMThu
Podium 3
Systems-Standards & Futures
Speakers
Prof Nicholas Goodwin
Professor
National University of Singapore
Introduction: Social prescribing has grown in policy and practice globally, but the current ‘state of play’ reveals an environment in which its development is characterised by considerable variation. This paper reports on the findings of a policy review that sought to distil the latest international trends and evidence on social prescribing to develop timely and relevant recommendations for policymakers to support informed decision-making both in Singapore and internationally. Methods: A rapid review of the evidence was undertaken to understand what the national and international experience tells us about the implementation and impact of social prescribing in policy and practice. A policy dialogue with senior decision-makers, health and social care professionals and academics reviewed these findings to develop key considerations for evidence-informed policymaking. Results: Social prescribing has a growing and positive evidence-base. However, more research and international coordination is needed to most appropriately position social prescribing within health systems, to understand its impact, and the requirements for sustainable growth. Specifically, the review raised key policy questions on how social prescribing can best be incentivised; whether it should be targeted to a specific patient cohort or more broadly applied; whether a national model for adoption should be preferred over contextually-specific approaches; how education and training needs can be met, including the potential risks associated with role professionalisation; and what regulation, governance and accountability should look like in an environment requiring co-productive partnerships? Discussion: There is no ‘one model’ for social prescribing. Robust evaluations are required to grow the evidence base for what works, in what contexts, and for which people. International collaboration is needed to promote knowledge and best practice. An ongoing policy dialogue is required to discuss issues essential to the future of social prescribing and so share knowledge, build consensus, and inform decision-making.